A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project
Ries A, Trottenberg P, Elsner F, Stiel S, Haugen D, Kaasa S, Radbruch L
Palliative medicine · 74 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2011-08-24 · Palliat Med · vol. 26 · número 4 · págs. 294–304
- Editorial
- SAGE Publishing
- Citado
- 126 citas · más que el 76% de estudios similares · 1.4× el promedio de su campo
- Referencias
- 46 trabajos
- Acceso
- Acceso abierto (revista)
- Áreas de investigación
- Nutrition and Health in Aging · Clinical Nutrition and Gastroenterology · Fatty Acid Research and Health
- Palabras clave
- fish oil, omega-3 fatty acids, eicosapentaenoic acid, cancer cachexia, advanced cancer, palliative care, clinical guideline development, adverse effects, quality of life
- MeSH
- humans, neoplasms, cachexia, fatty acids, omega-3, eicosapentaenoic acid, fish oils, dietary supplements, practice guidelines as topic
7 autores
- Anke Ries🇩🇪Universitätsklinikum Aachen; RWTH Aachen University
- Peter Trottenberg🇩🇪Universitätsklinikum Aachen
- Frank Elsner🇩🇪Universitätsklinikum Aachen; RWTH Aachen University
- Stephanie Stiel🇩🇪Universitätsklinikum Erlangen
- Dagny Faksvåg Haugen🇳🇴Norwegian University of Science and Technology; Haukeland University Hospital
- Stein Kaasa🇳🇴Norwegian University of Science and Technology; St Olav's University Hospital
- Lukas Radbruch🇩🇪University Hospital Bonn
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
The European Palliative Care Research Collaboration is developing clinical guidelines on cachexia in patients with advanced cancer. A systematic review on the use of fish oil/omega-3-fatty acids (n-3-FA)/eicosapentaenoic acids (EPA) in advanced cancer patients suffering from cancer cachexia was performed as part of the guideline development.
Methods
The systematic literature search in Medline on the use of fish oil/n-3-FA/EPA identified 244 papers, with 38 publications included in the final evaluation. Some smaller trials, often unrandomized and without a control group, reported a good effect of n-3-FA in patients with advanced cancer and cachexia. However, the results of the larger randomized controlled trials could not support the positive results, as they mostly did not find a significant effect.
Results
Adverse effects such as abdominal discomfort, fish belching, fish aftertaste, nausea and diarrhoea were reported with a low incidence. No serious adverse effects were documented, but adverse effects often had an impact on quality of life. This often limited dose escalations or even led to discontinuation of n-3-FA.
Conclusion
There is not enough evidence to support a net benefit of n-3-FA in cachexia in advanced cancer. On the other hand, adverse effects were infrequent, with no severe adverse effects. The results from the review led to a weak negative GRADE recommendation.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.